Fig 4. Kaplan–Meier curves for the secondary composite endpoint of doubling of serum creatinine or ESRD and for the single endpoint of ESRD in patients with CKD stage 4.

Kaplan–Meier curves show the proportion of patients with CKD stage 4 who reached (A) the composite endpoint of doubling of serum creatinine or ESRD or (B) ESRD considered as a single endpoint (secondary outcomes) in the placebo and octreotide-LAR groups during the 3-year study period. *Adjusted by age, sex, and baseline serum creatinine.°Adjusted by age, sex, and baseline serum creatinine and total kidney volume. CKD, chronic kidney disease; ESRD, end-stage renal disease; HR, hazard ratio; octreotide LAR, octreotide long-acting release.